VYZULTA Drug Patent Profile
✉ Email this page to a colleague
When do Vyzulta patents expire, and when can generic versions of Vyzulta launch?
Vyzulta is a drug marketed by Bausch And Lomb and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has fifty-three patent family members in thirty-eight countries.
The generic ingredient in VYZULTA is latanoprostene bunod. Two suppliers are listed for this compound. Additional details are available on the latanoprostene bunod profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vyzulta
A generic version of VYZULTA was approved as latanoprostene bunod by GLAND on April 29th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VYZULTA?
- What are the global sales for VYZULTA?
- What is Average Wholesale Price for VYZULTA?
Summary for VYZULTA
| International Patents: | 53 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 2 |
| Patent Applications: | 277 |
| Drug Prices: | Drug price information for VYZULTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VYZULTA |
| What excipients (inactive ingredients) are in VYZULTA? | VYZULTA excipients list |
| DailyMed Link: | VYZULTA at DailyMed |
Recent Clinical Trials for VYZULTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Icahn School of Medicine at Mount Sinai | Phase 4 |
| Bausch & Lomb Incorporated | N/A |
| University of California, San Diego | N/A |
Paragraph IV (Patent) Challenges for VYZULTA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VYZULTA | Ophthalmic Solution | latanoprostene bunod | 0.024% | 207795 | 1 | 2022-03-31 |
US Patents and Regulatory Information for VYZULTA
VYZULTA is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | AB | RX | Yes | Yes | 8,058,467 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VYZULTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 6,211,233 | ⤷ Start Trial |
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 7,629,345 | ⤷ Start Trial |
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 7,273,946 | ⤷ Start Trial |
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 7,910,767 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VYZULTA
When does loss-of-exclusivity occur for VYZULTA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Intellectual Property Organization (OAPI)
Patent: 356
Patent: Prostaglandin nitrooxyderivatives.
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VYZULTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 225771 | ⤷ Start Trial | |
| Australia | 740683 | ⤷ Start Trial | |
| Australia | 8438698 | ⤷ Start Trial | |
| Brazil | 9810163 | compostos liberadores de àxido nÍtricos. | ⤷ Start Trial |
| Canada | 2292836 | COMPOSITIONS PHARMACEUTIQUE DE PROSTAGLANDINES (PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS) | ⤷ Start Trial |
| China | 1260778 | ⤷ Start Trial | |
| Germany | 69808619 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch